Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials-Reference-Cited by-同舟云学术

Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials

Published:2021-02 Issue: Volume:64 Page:103203
ISSN:2352-3964
Container-title:EBioMedicine
language:en
Short-container-title:EBioMedicine

Author:

Huang Yunda,Naidoo Logashvari,Zhang Lily,Carpp Lindsay N.^ORCID,Rudnicki Erika,Randhawa April^ORCID,Gonzales Pedro,McDermott Adrian,Ledgerwood Julie,Lorenzo Margarita M.Gomez,Burns David,DeCamp Allan,Juraska Michal^ORCID,Mascola John,Edupuganti Srilatha,Mgodi Nyaradzo,Cohen Myron,Corey Lawrence,Andrew Philip,Karuna Shelly,Gilbert Peter B.,Mngadi Kathryn,Lazarus Erica^ORCID

Funder

Fred Hutchinson Cancer Research Center

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference43 articles.

1. UNAIDS. Global HIV & AIDS statistics - 2020 fact sheet. https://www.unaids.org/en/resources/fact-sheet Access date Sept 11, 2020. [Available from: http://www.unaids.org/en/resources/fact-sheet.

2. Twenty years of antiretroviral therapy for people living with hiv: global costs, health achievements, economic benefits;Forsythe;Health Aff (Millwood),2019

3. Recent advances in pre-exposure prophylaxis for HIV;Desai;BMJ,2017

4. Advancing global health and strengthening the HIV response in the era of the sustainable development goals: the international AIDS society-lancet commission;Bekker;Lancet,2018

5. Multiple roles for HIV broadly neutralizing antibodies;Haynes;Sci Transl Med,2019

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trial;PLOS Medicine;2024-06-24

2. Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV;Pharmaceutics;2024-04-27

3. A Randomised Clinical Trial of the Safety and Pharmacokinetics of VRC07-523LS Administered via Different Routes and Doses (HVTN 127/HPTN 087);2024-01-11

4. Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01;Nature Communications;2023-11-28

5. Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition;eBioMedicine;2023-07